OR WAIT 15 SECS
© 2020 MJH Life Sciences and BioPharm International. All rights reserved.
August 10, 2020
Introduction of ELEVECTA®, CEVEC’s fully scalable and stable production platform for AAV gene therapy viral vector manufacturing.
August 07, 2020
The companies have agreements to supply its mRNA-based COVID-19 vaccine to Japan and Canada, pending regulatory approvals in those countries.
The European Medicines Agency recently approved two European Novartis sites in France and Switzerland for the commercial manufacturing of chimeric antigen receptor T-cell cell therapies.
The award will help a bioanalytics startup commercialize instrument technology for pharmaceutical antibody manufacturers.
The company is working to ensure broad global access to its COVID-19 vaccine candidate, following approval from regulators.
Sanofi and GlaxoSmithKline have been selected to supply the US government and the European Union with millions of doses of their COVID-19 vaccine candidate.
August 06, 2020
The expansion will involve using the facilities’ existing central utilities and labs to supplement its small-scale and large-scale assets.
The expanded facility will feature two new 40-L and 300-L manufacturing vessels, a capsule filling line, and six drying tunnels that will add more than 10 million doses per annum to the site.
The therapy, indicated for a rare form of B-cell non-Hodgkin’s lymphoma, was developed by Kite, a Gilead company, which will manufacture the therapy at its facility in El Segundo, CA.
August 05, 2020
Healthcare groups met in late July 2020 to discuss the state of the US pharmaceutical supply chain and the impact of COVID-19.